“The findings suggest that lifetime classic psychedelic use is associated with lower odds of having had heart disease or diabetes in the past year,” lead study author and Oxford sociologist Otto Simonsson.
In a landmark trial, a cocktail of immunotherapy medications harnessed patients’ immune systems to kill their own cancer cells and prompted “a positive trend in survival.”
Ayushman Bharat, India’s flagship health insurance for the least privileged communities, will provide coverage for #trans individuals that includes support for sex-change operations.
The vaccine – called RTS,S and developed by PATH and GlaxoSmithKline – was proven effective in 2015. Now, after the success of pilot immunization programs in Ghana, Kenya, and Malawi, the World Health Organization says the vaccine should be rolled out across sub-Saharan Africa and in other regions with moderate to high malaria transmission. Having a safe, effective vaccine for one of the world’s deadly diseases – after more than a century of trying – is a historic milestone for medicine and public health.
BioNTech, the German company that developed Pfizer’s covid-19 vaccine, is now testing whether mRNAs can treat cancer in humans. The treatment has already completely shrunk tumors in mice.
A new study by researchers at Johns Hopkins Kimmel Cancer Center is showing a novel blood test can detect the presence of lung cancer with over 90% accuracy using artificial intelligence.
Nitzan Horowitz, the out Minister of Health in Israel, proclaimed, “There’s no difference between one blood and the other. Discrimination against gays in donating blood is over.”
Studies from Columbia University, University of California Berkeley, and other renowned institutions show that chlorpyrifos can damage the developing brains of children, causing reduced IQ, loss of working memory, and attention deficit disorders.
The clinical trials will start on August 19 and end sometime around spring 2023, according to the National Institutes of Health’s trial registry. They will involve 56 HIV-negative participants aged 18 to 56.
Targeting a pair of rare genetic blood diseases, the experimental therapy has so far been 100 percent effective in all 22 patients treated.
